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Abstract: Chronic Patellar tendinopathy (CPT) is a frequent overuse disorder in athletes and active people.
Sclerotherapy (ST) and prolotherapy (PT) are, among a wide range of conservative treatment options, two
promising therapies and have shown positive results in other tendinopathies. Since the treatments’ efficacy and
safety are still not defined, this review sought to answer questions on recommendations for use in clinical utility,
safety, and how to perform the injection in the most effective way. An electronic database search was conducted
following the PRISMA guidelines. Inclusion criteria were set up according to the PICOS-scheme. Included were
athletes and non-athletes of all ages with diagnosed painful CPT. Studies including patients suffering from patellar
tendinopathy which can be originated to any systemic condition affecting the musculoskeletal system (e.g.
disorders associated with rheumatism) and animal studies were excluded. Methodological quality (modified
Coleman Methodology Score) and risk of bias (Cochrane Risk of Bias Assessment Tool 2.0) were assessed by two
independent reviewers, with disagreements resolved with a third reviewer. The search yielded a total of 416 entries.
After screening titles, abstracts, and full texts, ten articles were found for qualitative analysis. The mean Coleman
Score was 64.57. Three randomized-controlled trials showed positive results with an increase in VISA-P score or a
decrease in VAS or NPPS, respectively. The non-randomized studies confirmed the positive results as well. Among
all ten studies no serious adverse events were reported. Based on this limited set of studies, there seems to be
some evidence that ST and PT may be effective treatment options to treat pain and to improve function in patients
with CPT. To strengthen this recommendation, more research is needed with larger volume studies and
randomized controlled studies with long term follow up.
Level of evidence: IV
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Introduction
Tendinopathy is known as an overuse condition that often
occurs in athletes or physically active people. Its cardinal
symptoms are defined as pain, swelling and impaired
function [43]. Besides Achilles tendinopathy (AT), chronic
painful patellar tendinopathy (CPT), also referred to as
jumper’s knee, is a frequently seen disorder. Its overall
prevalence among elite athletes is estimated at 14.2%, with
the highest incidence in volleyball (44.6%) and basketball
(31.9%) players [41]. Eccentric training has shown the best
evidence for treating CPT, but the less time consuming
and most efficient treatment option is still under debate
[19, 57]. Conservative treatment modalities include eccen-
tric training, extracorporeal shockwave therapy, or physio-
therapy. Research also reviewed the role of two injection
therapies such as Sclerotherapy (ST) and Prolotherapy
(PT) [15, 19]. After discovering that the origin of pain in
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tendinopathy arises from nerve endings runs parallel to
the small vessels into the tendon, Alfredson et al. assumed
that sclerosing the neovessels would destroy the nerve
endings, resulting in pain relief [4–6]. Sclerotherapy was
initially used for treating varicose veins [58]. The most
commonly used substance is Polidocanol, a topical anaes-
thetic, causing endothelial damage by interacting with the
lipid layer of intimate cells’ membranes [18]. Other deter-
gents that can be used for ST are sodium tetradecyl sulfate
and sodium morrhuate [18]. In 2002 Ohberg and Alfred-
son conducted a pilot study investigating the effect of ST
on chronic painful Achilles tendinopathy and showed en-
couraging results [49]. Further research may confirm these
findings [6, 68]. However, there are reports that do not
support that the neovessels are the source of pain [17, 63].
In the 1950s it was George Hackett who first introduced
Prolotherapy [24].(PT). The motive behind PT is similar
to ST. The mechanism of action of the mostly used sub-
stances, eg. hypertonic dextrose solution, is mainly gener-
ated by osmotic shock and dehydrating cells [7, 69]. By
causing local damage to the tendon it is assumed to in-
duce several effects including an inflammatory response
which results in a healing process. The detailed mechan-
ism remains unclear but seems to be multifactorial. Sen-
sorineural analgesic pathways are discussed as well [51, 52].
In pilot studies, Lyftogt and Maxwell also yielded promising
results for PT when treating the Achilles tendon in patients
with AT. Lyftogt injected hyperosmolar dextrose around the
paratenon and Maxwell targeted the tendon [42, 44].
Recently a systematic review with meta-analysis sug-
gested that there is weak evidence that ST and PT might
be effective treatments to treat pain in patients with AT
[46]. As there have been promising results on the treat-
ment of painful AT, this present systematic review is
aimed at evaluating the effect of ST and PT on chronic
painful patellar tendinopathy (CPT). By systematically
analysing the available literature this review sought to
answer questions on recommendations for the clinical
use, safety of the procedure, and how the injection is
performed effectively. Considering that this review’s aim
was to make a recommendation on the clinical use in
humans, animal studies were excluded.
Material and methods
This systematic review was conducted following the
PRISMA guidelines [45].
The flow-chart (Fig. 1) depicts the different steps of
the review procedure.
Study protocol
A study protocol has been edited and registered in 20/02/
2019 on PROSPERO- the international prospective register
of systematic reviews. The PROSPERO registration number
is CRD42019125803. The protocol can be accessed via
https://www.crd.york.ac.uk/prospero/display_record.
php?RecordID=125803 or can be provided on request.
Fig. 1 Flowchart of the selection process according to PRISMA guidelines
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Eligibility criteria
Eligibility criteria for suitable articles were set up accord-
ing to the PICOS scheme (Population, Intervention,
Outcome and Study design). Included were athletes and
non-athletes of all ages with diagnosed painful CPT. Studies
including patients suffering from patellar tendinopathy
which can be associated with any systemic condition affect-
ing the musculoskeletal system (e.g. disorders associated
with rheumatism) and animal studies were excluded. Studies
on interventions with injection treatments that describe a
sclerosing mechanism of action addressed to destroy neo-
vascularisations or prolotherapy (e.g. hyperosmolar glucose
solution) were included. The injection had to target the pa-
tellar tendon. Control groups included patients that received
any other treatment, such as surgery (e.g. arthroscopic shav-
ing), other injection treatment (e.g. platelet-enriched-plasma,
glucocorticoids), conservative treatment (e.g. eccentric train-
ing), different dosages or placebo. Studies investigating pain
and function as outcome variables were included in this
review. All published studies describing one of the following
designs were eligible for further analysis: randomized-
controlled trial (RCT), quasi RCT, prospective study, retro-
spective study, and case reports. There were no restrictions
in language and date of publication.
Search
The following electronic databases were searched:
MEDLINE via Ovid, BIOSIS Previews and Archive via
Ovid, CINAHL via EBSCOHost, SportDiscus via EBS-
COHost, CENTRAL (Cochrane Central Trial Register of
Controlled Trials) refined to trials via Cochrane Library,
Web of Science, Embase. The last database searches
were conducted on 27 February 2019 and on 8 March
2019 (Embase) respectively. To find additional topic-
related publications, a Google Scholar search using the
term “patellar tendinopathy sclerotherapy prolotherapy”
was performed. Furthermore, the reference lists of the
eligible articles were screened for further yields. The
search strategy was based on the search strategy of a
previous work from the same group and adjusted ac-
cording to the new topic [46]. The search strategy was
developed by two reviewers (OM, AH). The full Ovid
search strategy is stated in the Additional file 1.
Study selection
After removing all duplicates, titles and abstracts of the
studies were screened by two reviewers independently
(OM, MB) by the help of “Rayyan” a free web-based
semi-automatic screening tool [50]. Disagreements were
discussed and resolved by seeking consensus and by the
help of a third independent reviewer (AH). When title
and abstract met inclusion criteria full text was assessed
for eligibility. Again, disagreements were resolved by the
help of a third reviewer (AH).
Data collection
As the primary outcome measure, level of pain by VAS
(visual analogue scale), level of dysfunction by the VISA-
P score (Victorian Institute of Sport Assessment -Patel-
lar score) or any similar method for measuring was de-
fined. Visual Analogue Scale is a single-item tool to
quantify the level of pain on a 0–100 mm linear scale (0
the best, 100 the worst). VAS score has shown good reli-
ability to assess disability in patients with chronic mus-
culoskeletal pain [10]. The VISA-P score is a multi-item
questionnaire measuring pain and dysfunction of the pa-
tellar tendon. It is a reliable instrument to judge the clin-
ical severity of patellar tendinopathy [65]. Further
outcome measures could be the tendon thickness mea-
sured by ultrasound control, the safety of the interven-
tion measured by the number of reported adverse events
(AE), patient’s satisfaction with the treatment, as well as
the time to return to the same level of sport respectively
to previous level of activity and the usage of different
substances or dosages.
Individual study data were extracted and imputed
manually into a spreadsheet using the full text by OM
and confirmed by AH. Author names, year of publica-
tion and the study type were extracted (study details).
Number of patients (split in male and female), the num-
ber of treated tendons, the mean age of the participants,
the mean duration of symptoms and mean follow-up
were also extracted (population details). Three-month
follow-up (12 weeks) was defined as main follow-up for
data extraction. Furthermore, data on substance and
dosage, control groups, pre and post outcome values
from primary parameters (i.e. VISA-P or VAS score) and
AE were extracted (intervention data). Central tenden-
cies, measures of variability and p-Values of the outcome
parameters under investigation were extracted (outcome
details).
In case of incomplete or missing data, corresponding
authors were contacted. This was unsuccessful for three
studies [31, 61, 67]. Nevertheless, these studies were in-
cluded and only the presented data processed.
Quality and risk of bias
The risk of bias was double-assessed by two reviewers
independently (OM, MB) by using the Cochrane Risk of
Bias Assessment Tool 2.0 to evaluate the RCTs [28]. We
did not apply the Cochrane Risk of Bias Assessment
Tool for the non-RCTs, since it was specifically designed
for the evaluation of RCTs and is not easily applicable
for the non-RCTs [29]. The methodological quality of
the studies was independently analysed by two reviewers
(OM, MB) using the modified Coleman Methodology
Score (mCMS) [34]. Disagreement was minor, discussed
and resolved by seeking consensus by the help of a third
independent reviewer (AH). Classification and
Morath et al. Journal of Experimental Orthopaedics            (2020) 7:89 Page 3 of 11
interpretation of the quality of the included studies was
based on the mCMS values as follows: 0–25 (poor), 26–
50 (fair), 51–75 (good) and 76–90 (excellent).
Statistical analysis
Because of the very low number of randomized con-
trolled trials (RCT), the observed high methodological
heterogeneity observed across the studies (RCT and
non-RCT) and missing data statistically pooling of the
data seemed not plausible. Therefore, meta-analysis of
the individual study results was omitted.
Results
A total of 415 records were identified through this data-
base search. One additional record was found by screen-
ing suitable articles’ references. Therefore, 416 records
were investigated in total. After removing duplicates,
302 records’ abstracts and titles were screened and 274
of them excluded based on the a priori set exclusion
criteria. The remaining 28 articles (26 full-text articles
and two abstracts) were assessed for eligibility. Another
16 articles were excluded after full-text assessment. Rea-
sons for exclusion were: no injection reported at all (6)
[2, 8, 22, 36, 48, 66], no injection into the patellar tendon
(8) [12, 21, 25, 26, 54, 56, 59, 70], no new study data
(respectively they reported on the same study data of an
included study) [60] or animal studies (1) [20]. Thus,
twelve articles were included in the systematic review
and were suitable for qualitative synthesis. Regarding
the abstracts, no full-text article was available even
after contacting the corresponding authors [47, 62]
Therefore, these studies were also excluded, reducing
the final number of studies for further analysis in this
systematic review to ten.
Figure 1 shows the detailed selection process in a flow-
chart according to the PRISMA guidelines. Regarding
the type of therapy, eight studies investigating the effect
of ST and two studies on PT were included. Referring to
the study design, three randomized controlled trials
comparing verum injection to placebo injection [31],
arthroscopic shaving [67] or placebo injection and usual
care consisting of stretching and exercise [64], three pro-
spective studies [3, 33, 53] and one case report [22] were
included. In addition, three follow-up investigations of
the two ST RCTs [30, 32, 61] were also included, al-
though no new injection was administered, since their
findings might provide important information on long-
term outcome. The follow-up studies were treated as
follow-up of the original study, not as a separate study.
Tables 1 and 2 illustrate the main findings of the included
studies. Taken all studies into account, 343 tendons are
summarized, 231 (67.3%) of which received ST while 112
(32.7%) tendons were targeted by means of PT. The mean
number of injections for patients treated with ST was 2.7.
One PT study reported the median number of injections
received (median = 4 (range 2–8)) [53] and one study
reported a mean number of injections of 3.8 [64]. Gender
distribution, when reported across studies was not equivo-
cal (male patients = 174 (90.2%); female patients = 19
(9.8%)). Mean age of the patients was 25.9 years (range 9–
58). The mean duration of CPT symptoms, when reported,
was 22.4months and the mean follow-up ranged from 4 to
46months.
All ST studies used Polidocanol as sclerosing agent.
One study injected Polidocanol in a concentration of 5
mg/ml [3], all other studies applied a concentration of
10 mg/ml [22, 31, 33, 67]. In one RCT the investigators
injected a placebo solution made of adrenaline 5 μg/ml
and lidocaine 5 mg/ml to obtain the same immediate
effect [31]. The PT RCT used 12.5% dextrose solution
and lidocaine 10mg/ml as a placebo solution [64]. The
non RCT PT study also used a dextrose solution to treat
the patellar tendon. Ryan et al. injected a 25% dextrose
solution [53].
Table 1 Demographics
Author Year Study type Patients No of tendons Mean age Mean duration
of symptoms
Mean follow-up
m f years months months
Sclerotherapy
Alfredson 2004 prospective 12 3 15 29 23 6
Gisslén 2006 case report 1 0 1 25 9 4
Hoksrud 2006 RCT 28 5 43 24.9 37.1 27
Willberg 2011 RCT 43 2 52 26 22 46
Hoksrud 2012 prospective 101 120 27 17 15
Prolotherapy
Ryan 2011 prospective 39 6 47 38.3 21.8 11
Topol 2011 RCT 51 3 65 13.3 not reported 12
m male, f female, RCT Randomized controlled trial
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Quality assessment and risk of bias
Mean modified Coleman Score of all studies was 64,57
which is rated as good quality. There was one article de-
fined as fair quality [22], five articles having good quality
[3, 33, 53, 64, 67] and one article rated as excellent qual-
ity [31]. No study was defined as having poor quality.
Table 3 presents an overview of the mCMS assessment.
Figure 2 shows an overview of the risk of bias (RoB)
assessment. The Hoksrud’s RCT had an overall risk of
bias rated as “some concerns” because no raw data was
available. The Willberg study showed an overall high
risk of bias. Since a blinding of the two investigated in-
terventions (shaving vs. injection) was not possible due
to obvious reasons, we rated this domain of high risk of
bias, which mainly attributes to the overall risk of bias.
The Topol study showed also an overall high risk of bias,
since the investigators and participants were unblinded
after 3 months and further injections were performed.
As stated above the application of Cochrane’s RoB Assess-
ment Tool is not developed for non-RCTs. All non-RCTs
were treated as having an overall high risk of bias.
Individual studies
RCT Sclerotherapy
Hoksrud et al. compared the effect of Polidocanol against
placebo injections containing adrenaline and lidocaine in
their double blinded RCT of 2006 [31]. They reported a sig-
nificant pain reduction, improvement in VISA score and
patients’ satisfaction with the treatment. The treatment
group showed an increase in VISA-P score from 54 to 62
at the 4months follow-up, whereas the control group
showed no changes in VISA-P score. After 4months the
control group crossed over and received sclerosing injec-
tions as well. After 8months, the VISA-P score for both
groups after receiving injections was 75, which also reflects
the minimum clinically important difference (MCID). The
MCID is defined as an absolute change of more than 13
points, respectively a relative change of 15.4–27% of the
baseline VISA-P score [27]. Nearly one third (14 tendons)
of the patients received additional treatment (6 patients
tendon surgery, 8 patients non tendon surgery (e.g. debride-
ment of chondral defects or resection or removal of a plica
medialis) after sclerosing injections. The VISA-P score in-
creased further from 75 (8months follow-up) to 89 (44
months follow-up) for the patients (23 tendons) who did
not receive additional treatment (surgery). For the patients
who had undergone surgery VISA-P score improved to 91
(tendon surgery) and 92 (non-tendon surgery) [30].
Twenty-eight of 33 patients were back to full training with
no or only mild symptoms after 12months [31].
In one follow-up investigation, focussing on the ultra-
sound findings of the study population, the investigators
stated, that in about two third of patients with patellar
tendinopathy neovascularisations can be expected. They
were not able to show a correlation between an im-
provement in VISA-P score and structural changes after
the injection therapy [32].
Table 2 Intervention







Alfredson 2004 prospective polidocanol 5 mg/ml na 79.7 19 2.7 none
Gisslén 2006 casereport polidocanol 10 mg/ml na 90 0 0 1.0 none
Hoksrud 2006 RCT polidocanol 10 mg/ml adrenaline 5 μg/ml
+lidocaine hcl 5 mg/ml
VISA VISA VISA 3.1 (intervention
+ crossover)
none
Willberg 2011 RCT polidocanol 10 mg/ml arthroscopic shaving 69 41.1 (17) na none
Hoksrud 2012 prospective polidocanol 10 mg/ml na VISA VISA VISA 2.5 none
Prolotherapy
Ryan 2011 prospective 25% dextrose solution na 51.1 25.8 median 4 none
Topol 2011 RCT 12.5% dextrose solution lidocaine 10 mg/ml NPPS NPPS NPPS 3.8 none
VAS Visual Analogue Scale, no number, FU Follow-up, RCT Randomized controlled trial, na not available, VISA Victorian Institute of Sport Assessment, NPPS Nirschl
Pain Phase Scale
Table 3 modified Coleman Methodology Score
Author Coleman Score Rating
Alfredson 2004 53 good
Gisslén 2006 43 fair
Hoksrud 2006 83 excellent
Topol 2011 68 good
Willberg 2011 73 good
Hoksrud 2012 72 good
Ryan 2011 60 good
Overall 64.57 good
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The second RCT by Willberg and colleagues, investi-
gated the effect of sclerosing Polidocanol injections
versus arthroscopic shaving [67]. The authors showed
good results for both cohorts but stated that arthro-
scopic shaving led to a greater pain reduction and more
satisfaction with the treatment. The VAS score for the
sclerosing group decreased from 69.0 pre-treatment to
41.1 at follow-up. VAS score for the arthroscopy group
fell from 76.5 to 12.8 and was significantly lower than
VAS for the ST group at follow-up (p = 0.001).
In a medium-term follow-up study the same researchers
sought to investigate the effect of both treatments after
three to 5 years [61]. They reported good clinical outcomes
for both treatment modalities, showing a significantly faster
rehabilitation for the arthroscopic group. VAS score in the
sclerosing group further decreased to 17 but remained
stable (13) in the arthroscopic group. There was no statisti-
cally significant difference between both groups. For both
groups, the researchers found significant changes referring
to structural changes and neovascularisation in the ultra-
sound examination (ST group p = 0.013, arthroscopy group
p < 0.001). Furthermore, positive and statistically significant
relationships between the existence of neovascularisations
and VAS score during activity (r = 0.63, p < 0.0001)
and between the VAS score and structural changes
(r = 0.52, p < 0.0001) were observed.
RCT Prolotherapy
Topol et al. investigated the effect of hyperosmolar dex-
trose injections to treat Osgood-Schlatter Disease (OSD)
in children and adolescents [64]. They divided 54 patients
with clinically diagnosed OSD in 3 groups. The control
group had to do 3months of supervised stretching and ex-
ercise therapy, the placebo group received monthly injec-
tions of lidocaine 10mg/ml and the intervention group
was treated with 12.5% hyperosmolar dextrose solution.
At the 3months follow-up the intervention group showed
a bigger drop in Nirschl Pain Phase Scale (NPPS) com-
pared to the other groups. Mean NPPS difference after 3
months was 3.9 for the intervention group compared to
2.4 for the placebo group and 1.2 for the control group
(p < 0.0001 between all groups). After 3 months investiga-
tors and patients were unblinded and all groups offered
further monthly dextrose injections for at max 9 more
months until a satisfying level of symptom control was
achieved. After 12months they showed a higher success
rate in the patients receiving dextrose injections compared
to the patients not receiving dextrose injections (32/38 vs.
6/13, p = 0.024). All patients of the intervention group
could participate in sports after treatment and 14 out of
21 knees were asymptomatic [64].
Non-RCT Sclerotherapy
This search led to three non-RCT articles treating the
patellar tendinopathy with sclerosing injections. Alfred-
son et al. carried out a pilot study with a prospective
design in 2004. Fifteen patients with sonographically
confirmed diagnosis of patellar tendinopathy received a
mean of 2.7 injections (SD = 1.58) of Polidocanol (5 mg/
ml). The mean baseline VAS was 79.7 and reduced to 19
(p < 0,001) in the follow-up examination. Twelve out of
15 patients were satisfied with the treatment. Beside the
VAS, the amount of neovascularisation was documented
with a score ranging from zero to four. The mean base-
line neovascularisation was estimated 3.87 (SD = 0.35)
and decreased to 1.69 (SD = 1.54, p < 0.001) after scleros-
ing treatment [3].
In 2012 the research group of Hoksrud conducted a
prospective trial with 120 tendons (101 patients) [33].
The researchers injected Polidocanol in a concentration
of 10 mg/ml from the ventral site of the tendon in a
mean of 2.5 injections. Twenty-two patients had add-
itional knee surgery during the follow-up period and
additional 29 patients underwent non-surgical treatment
Fig. 2 Summary of the risk of bias assessment
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options. Hoksrud et al. reported a moderate improve-
ment in VISA-P score. For all patients who were
followed up, VISA-P increased from 39 at baseline to 65
at the 24months follow-up. The group that was treated
without surgery showed an increase in VISA score from
39 to 68, while the surgery group had an increase from
43 to 57.
In a case study, Gisslén et al. cured a 25-year-old Olympic
weightlifter suffering from CPT. After one injection of
Polidocanol (10mg/ml) and a two-week rehabilitation
phase, the athlete was back to full tendon load activity.
VAS before the treatment during weightlifting was 90 and
went down to 0 during weightlifting after ST. Furthermore,
Gisslén et al. reported on a reduction of neovascularisation
in the 4months follow-up [22].
Non-RCT Prolotherapy
One study on PT could be included in this systematic
review. Ryan et al. investigated in a prospective pilot
study the effect of a 25% dextrose solution to treat the
painful patellar tendon. The mean baseline VAS in daily
living for the 47 included patients was 51.1 (SD = 22.9).
After having received a median of 4 injections (±3), VAS
significantly fell to 25.8 (SD = 20.1) (p < 0.001). More
than half of all patients (25 out of 47) stated reduction
of pain of more than 50%. Furthermore, the authors im-
plied that dextrose injections might enhance tendon re-
modelling, since they could show a decrease in tendons
with intratendinous tears (22 to 10 tendons) and reduc-
tion of hypoechogenicity (13 to 5). Nevertheless, Ryan
et al. could not show a relationship between neovessels
and tendon pain [53].
Adverse effects
All trials stated that there occurred no serious AE (SAE)
during the treatment. However, in the Ryan study, three
patients reported an increase in pain after treatment,
which can be classified as AE [53]. In the Topol study <
10% of the participants made use of acetaminophen to
control postinjection pain [64].
Discussion
The aim of this systematic review was to evaluate the effect
of sclerotherapy (ST) or prolotherapy (PT) on pain and
function in patients suffering from CPT. By systematically
searching electronic databases and references all available
studies on this topic should be included to be able to make
a clear statement on the effectiveness of both therapies.
The two RCTs on ST showed positive and clinically
relevant results in terms of a reduction in pain or an
increase in function, respectively. However, in the Willberg
study, pain was statistically significant lower in the arthros-
copy group as compared to the sclerotherapy group indicat-
ing a better improvement in pain scores after arthroscopy.
The RCT on PT confirmed the findings with all pa-
tients of the intervention group participating in sports
and 14 out of 21 asymptomatic knees. At first sight OSD
might not appear as a typical tendinopathy condition,
but OSD ultrasound studies suggest that tendinopathy
features including neovessels can be found in the distal
patellar tendon [16, 39, 55]. Therefore, this study was
included.
The non-RCT studies on ST and PT underlined the
positive findings of the RCTs. Only one study reported
on a moderate improvement. This might be attributed
to the fact, that the injection was performed from the
ventral side of the patellar tendon. It is recommended to
perform the injection from the dorsal side of the patellar
tendon where the neovessels enter the tendon [3, 17].
The methodological quality assessment of the included
studies demonstrated good quality (mCMS = 64.57
points). Nevertheless, there was only one of the included
studies rated with excellent methodological quality. This
clearly reveals the need of more high-quality studies.
Methodological quality was flawed by no adequate
randomization and lack of control group. No study was
of poor methodologic quality.
Risk of bias assessment showed an overall high risk in
two RCT study. In one of these studies, a blinding of the
two interventions was not feasible, which resulted in a
high risk of bias. In the other study, patients and phys-
ician were unblinded after 3 months. We defined all
non-RCTs as high overall risk of bias, which underlines
the need for further RCTs. All RCT were rated of “some
concerns” in the domain “selection of the reported re-
sults” because we had no raw data available. All other
domains were rated of low quality. Hence, there conclu-
sion and results remain usable within the constraints of
very high likelihood for risk of bias.
To our knowledge this is the first systematic review
focussing only on the effectiveness of ST and PT on pain
and function in patients with CPT. Therefore, it is
difficult to compare it to similar reviews. Larsson et al.
conducted a systematic review of RCTs on treatment
options in patients with patellar tendinopathy. Their
main outcome was the VISA-P score, respectively VAS
score. They included 13 studies with 612 patients in
total. Larrson et al. stated that eccentric squats have the
best evidence, whereas ST among others might have a
benefit as well. They were not able to make a clear state-
ment, since they included only one study on sclerother-
apy [40]. Two more recent systematic reviews on the
treatment of CPT concluded also that that eccentric
training has the best evidence while there was limited
evidence for ST [19, 40] to have an effect on pain and
function in patients with CPT. Among other factors this
is accounted for by the lack of more suitable studies.
What all these reviews have in common is the statement,
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that more high-quality research and studies are needed
to be able to make recommendations for the use of ST
and PT in clinical routine when working with patients
suffering from CPT.
Since the selected studies were found to be unsuitable
for a quantitative synthesis and no meta-analysis was
conducted, a clear statement on the clinical relevance of
an overall effect size of ST and PT on pain and function
in patients with CPT cannot be presented. Yet, based on
the limited set of studies included in this analysis and
taking in considerations the high likelihood for risk of
bias in the selected studies, the qualitative synthesis of
the individual studies’ effect sizes suggests a promising
clinical effect. Nevertheless, the true size of this effect is
still to be determined, which underlines the need of
more research in this field.
Safety
Regarding safety of the interventions, PT and ST can be
considered safe, as three AEs (increase in pain), but no
serious adverse events (SAE) were reported. Taken all in-
cluded studies, there were multiple injections performed
in 343 tendons. As far as we know, there is no existing
definition of a safe intervention regarding the occurrence
of AEs. Bearing in mind that the total number of injec-
tions and tendons is small for a final conclusion and most
studies are underpowered to detect AEs, since they did
not comment on a systematic AE screening, we are of the
opinion that both therapies can be considered safe. A
recent systematic review on the effect of ST and PT on
painful Achilles tendinopathy underlined these findings.
The authors reported on only three, partially debatable,
adverse events compared to more than 600 injections [46].
The adverse events occurring were a lesion of Nervus sur-
alis due to an injection from the lateral side, although the
injection is normally performed from the medial side to
reduce the risk of lesions, one case of Embolia cutis medi-
camentosa, and a cutaneous reaction after injection, which
can lead to necrosis and a questionable partial tear of
the Achilles tendon [13, 35, 44]. In their well-designed
systematic review, Coombes et al. sought to investigate
the efficacy and safety of several injection therapies on
tendinopathy. They acknowledge that beside pain while
injecting, sclerosant and prolotherapy injections are a
safe procedure [15].
As case numbers are small for treating tendinopathy,
the safety of both procedures still need to be investigated
and should be addressed in further trials. General indica-
tions of possible complications using Polidocanol or any
sclerosing agent can come from its origin – sclerosing
varicose veins. The treatment is known to be safe, and
complications are very rare. A big multicentre registry
study observed in 12,173 sessions 49 (0.4%) complica-
tions [23]. The Australian Polidocanol study came to the
same conclusion. In 16,804 injections into varicose veins,
spider veins and venules, there were 154 (0.9%) compli-
cations (including allergic reactions) [14]. As mentioned
before this has to be understood as a general indication
since there were no injections in patellar tendons. It
seems to have foamed sclerosants connected to more
adverse events than liquid sclerosants (0.22% vs. 0.58%)
[23]. Even serious neurological events are described for
patients with patent foramen ovale after using foamed
sclerosant [11, 38].
Limitations
This systematic review, aimed to provide an extensive
overview on the effectiveness of ST and PT on pain and
function in patients with CPT, has some limitations.
First, there is some potential risk of incomplete retrieval
bias. Although a comprehensive search strategy was de-
veloped, it cannot be assured to really have captured all
existing trials on this topic. Having included all types of
study designs made the search more sensitive and may
have reduced the methodological quality of the included
studies to a certain extent. Unfortunately, based on this
small set of retrieved studies, it was not plausible to per-
form a meta-analysis since between studies’ heterogen-
eity was too high and raw data of three out of the ten
studies were missing. A quantitative synthesis could have
assessed a more accurate possible clinical effect size of
ST and PT procedures on pain and function in such
patients. At the same time this emphasizes the demand
of more methodological well-performed studies. Most of
the studies were set up in a single-arm design. Thus,
there is a potential risk of bias, since we cannot exclu-
sively assign the positive effects to the injections. Unfor-
tunately, some authors did not respond to our request
on raw data and additional information on their studies.
This prevents us from being able to draw more conclu-
sive statements. Regarding data extraction, we defined
the three-month follow-up as main follow-up point. Un-
fortunately, follow-up time points were not consistent.
Therefore, we extracted all available follow-ups. As a re-
sult, comparability of follow-ups is reduced. Further-
more, we have to note the missing comparison to other
treatments. As the Willberg study showed a greater pain
reduction and satisfaction with the arthroscopic shaving,
it would be of interest how sclerotherapy and prolotherapy
perform compared to other treatments. As the ESSKA
emphasizes, the most common approach to treat patellar
tendinopathy is an exercise-based treatment [1]. To
strengthen the recommendation for the use of sclerother-
apy and prolotherapy a RCT with sclerotherapy compared
to an exercise-based regime could have a big impact.
Some questions are still unanswered and should be
addressed in upcoming studies. It is still debatable,
whether ST or PT is favored when comparing their
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effect on pain and function in patients with CPT. Thus,
more direct head-to-head high-quality trials are needed.
Furthermore, in such studies important covariates
should be analyzed. For example, it is still not clear, in
which dose and concentration Polidocanol is used most
effectively to reduce pain and increase function in
patients with CPT. Most of the studies used up to 2ml
per injection of 10 mg/ml Polidocanol resulting in a
mean of 2.7 injections per patient to treat the patellar
tendinopathy. Comparing these findings to the system-
atic review on Achilles tendinopathy, where injections of
5 mg/ml Polidocanol resulted in a mean of 2.6 injections,
it is questionable whether the concentration makes a de-
cisive difference. A RCT from Willberg comparing two
different concentrations of Polidocanol can confirm this
consideration [68].
It is noteworthy to mention that PT shows a mean of
approximately 4 injections. Most of the studies had an
interval of 4 weeks, resulting in a treatment duration of
16 weeks for the PT treatment. Comparing both therap-
ies under this point of view, one can assume ST being
superior, since treatment duration will be shorter. This
might have a significant impact on patients, especially
on athletes during competition season. Following this
consideration, the question of shortening the interval re-
mains unanswered as well. Having a short duration of
treatment could make the injection treatments more
attractive to athletes, since their return to sport and
competition will be sooner. In comparison the standard
procedure of eccentric training provides at least a treat-
ment period over 12 weeks and is known to be painful
[37]. Therefore, future studies should focus on shorten-
ing the interval.
Further it is conceivable that a combination of differ-
ent treatment options can improve the outcome. Yelland
et al. showed a faster improvement in VISA-A score
combining Prolotherapy and eccentric training [69]. In
another recent study a combination of eccentric training
and high-volume injections with and without corticoste-
roids demonstrated promising results [9]. This suggests
further research on combined treatment schemes.
Conclusions
Based on the limited set of studies included in this
systematic review it seems that there is but very weak
evidence that ST and PT might be effective treatment
options to reduce pain and increase function in patients
with CPT. The present review also showed that 3 out of
295 injections (about 1%) caused even more pain. This
finding is corroborated with other studies and this num-
ber of AEs is considered to be acceptable. Due to a lack
of high-quality RCTs, a strong recommendation for daily
use in the clinical setting when treating such patients
cannot be made to date. This emphasizes the need of
more high-quality RCTs in a double-blinded design and
including direct head-to-head comparisons to underline
the effectiveness and use of ST and PT. Finally, once
effectiveness of the treatment alternatives has been
established, their financial efficiency should also be analyzed
using cost-effectiveness studies or cost-utility studies.
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